Truxima (rituximab) vs Jaypirca (pirtobrutinib)
Truxima (rituximab) vs Jaypirca (pirtobrutinib)
Truxima (rituximab) is a monoclonal antibody that targets the CD20 protein on the surface of B cells, commonly used in the treatment of certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and rheumatoid arthritis. Jaypirca (pirtobrutinib), on the other hand, is a Bruton's tyrosine kinase (BTK) inhibitor that interferes with the signaling that helps B cells multiply and survive, and is used for treating mantle cell lymphoma and CLL, particularly in patients who have received prior treatments. When deciding between Truxima and Jaypirca, it is crucial to consider the specific type of blood cancer, previous treatments, and individual patient factors such as the presence of certain mutations and overall health, as these will influence the effectiveness and suitability of each medication.
Difference between Truxima and Jaypirca
| Metric | Truxima (rituximab) | Jaypirca (pirtobrutinib) |
|---|---|---|
| Generic name | Rituximab | Pirtobrutinib |
| Indications | Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis | B-cell malignancies |
| Mechanism of action | CD20-directed cytolytic antibody | Bruton's tyrosine kinase inhibitor |
| Brand names | Truxima, Rituxan, MabThera | Jaypirca |
| Administrative route | Intravenous infusion | Oral |
| Side effects | Infusion reactions, fever, lymphopenia, chills, infection | Thrombocytopenia, neutropenia, anemia, diarrhea, fatigue |
| Contraindications | Severe active infections, severe immunodeficiency | None known specifically; generally, hypersensitivity to pirtobrutinib |
| Drug class | Monoclonal antibody | Tyrosine kinase inhibitor |
| Manufacturer | Celltrion Healthcare, Genentech | Lilly |
Efficacy
Truxima (rituximab) Efficacy in Lymphoma
Truxima, a biosimilar to the original rituximab product, is a monoclonal antibody that targets the CD20 antigen on the surface of pre-B and mature B lymphocytes. It is used in the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). In NHL, Truxima has been shown to be effective when used in combination with chemotherapy. Clinical trials have demonstrated that the addition of rituximab to chemotherapy regimens improves overall survival and response rates in patients with various subtypes of NHL, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
For chronic lymphocytic leukemia, Truxima has also shown efficacy, particularly when used in combination with chemotherapy. Clinical studies have indicated that rituximab, in combination with fludarabine and cyclophosphamide (FC), significantly improves overall survival and progression-free survival compared to chemotherapy alone. The use of Truxima has become a standard of care in the treatment of these B-cell malignancies due to its ability to improve patient outcomes.
Jaypirca (pirtobrutinib) Efficacy in Lymphoma
Jaypirca, also known as pirtobrutinib, is a novel, highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor. It is designed to overcome resistance to other BTK inhibitors and has shown promise in the treatment of B-cell malignancies, including mantle cell lymphoma (MCL) and other forms of NHL. In clinical studies, Jaypirca has demonstrated efficacy in patients who have been previously treated with other BTK inhibitors, indicating its potential as a treatment option for patients with relapsed or refractory disease.
The efficacy of Jaypirca in lymphoma is particularly noteworthy in the context of MCL, where patients often relapse after initial therapies. In early clinical trials, Jaypirca has shown a favorable safety profile and significant anti-tumor activity in patients with B-cell malignancies, including those with MCL. While further research is needed to fully establish the efficacy of Jaypirca in a broader lymphoma population, the preliminary data suggests that it may offer a new therapeutic avenue for patients with BTK inhibitor-resistant forms of the disease.
Regulatory Agency Approvals
Truxima
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Jaypirca
-
Food and Drug Administration (FDA), USA
Access Truxima or Jaypirca today
If Truxima or Jaypirca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us